Ibnsina Pharma (EGX:ISPH)
Egypt
· Delayed Price · Currency is EGP 11.21
+0.01 (0.09%)
At close: Mar 5, 2026
Ibnsina Pharma Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 76,597 | 55,842 | 33,949 | 22,264 | 21,733 | Upgrade
|
| Revenue Growth (YoY) | 37.17% | 64.49% | 52.48% | 2.45% | 16.35% | Upgrade
|
| Cost of Revenue | 70,148 | 51,446 | 31,434 | 20,648 | 20,103 | Upgrade
|
| Gross Profit | 6,449 | 4,397 | 2,515 | 1,617 | 1,630 | Upgrade
|
| Selling, General & Admin | 2,681 | 1,931 | 1,289 | 1,076 | 829.22 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 2.75 | Upgrade
|
| Other Operating Expenses | -82.44 | -7.71 | -9.46 | -7 | - | Upgrade
|
| Operating Expenses | 2,836 | 2,139 | 1,364 | 1,135 | 962.17 | Upgrade
|
| Operating Income | 3,614 | 2,258 | 1,152 | 482.22 | 667.35 | Upgrade
|
| Interest Expense | -2,559 | -1,686 | -1,044 | -477.09 | -284.18 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.2 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 4.67 | 55.35 | 38.53 | 38.41 | 0.28 | Upgrade
|
| Other Non Operating Income (Expenses) | 17.49 | 71.67 | 121.65 | 131.01 | 86.01 | Upgrade
|
| EBT Excluding Unusual Items | 1,077 | 698.77 | 267.75 | 174.55 | 469.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 1.56 | -1.13 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 2.95 | 1.39 | 0.75 | 4.25 | Upgrade
|
| Legal Settlements | - | - | - | - | -48 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.37 | Upgrade
|
| Pretax Income | 1,077 | 703.28 | 268.02 | 175.31 | 425.34 | Upgrade
|
| Income Tax Expense | 125.36 | 88.72 | 54.74 | 4.43 | 110.95 | Upgrade
|
| Earnings From Continuing Operations | 951.98 | 614.56 | 213.27 | 170.87 | 314.4 | Upgrade
|
| Minority Interest in Earnings | -0 | 0 | 0.39 | 1.71 | 0.33 | Upgrade
|
| Net Income | 951.98 | 614.56 | 213.66 | 172.58 | 314.73 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 116.77 | 40.52 | 36.95 | 28.4 | Upgrade
|
| Net Income to Common | 951.98 | 497.8 | 173.14 | 135.63 | 286.33 | Upgrade
|
| Net Income Growth | 54.90% | 187.63% | 23.80% | -45.16% | 40.09% | Upgrade
|
| Shares Outstanding (Basic) | 1,253 | 1,008 | 1,008 | 1,008 | 1,302 | Upgrade
|
| Shares Outstanding (Diluted) | 1,253 | 1,008 | 1,008 | 1,008 | 1,302 | Upgrade
|
| Shares Change (YoY) | 24.27% | - | - | -22.58% | 16.25% | Upgrade
|
| EPS (Basic) | 0.76 | 0.49 | 0.17 | 0.13 | 0.22 | Upgrade
|
| EPS (Diluted) | 0.76 | 0.49 | 0.17 | 0.13 | 0.22 | Upgrade
|
| EPS Growth | 53.90% | 187.51% | 27.65% | -38.81% | 33.78% | Upgrade
|
| Free Cash Flow | -805.66 | -1,187 | -228.23 | -436.58 | -487.96 | Upgrade
|
| Free Cash Flow Per Share | -0.64 | -1.18 | -0.23 | -0.43 | -0.38 | Upgrade
|
| Dividend Per Share | - | 0.160 | - | - | 0.086 | Upgrade
|
| Gross Margin | 8.42% | 7.87% | 7.41% | 7.26% | 7.50% | Upgrade
|
| Operating Margin | 4.72% | 4.04% | 3.39% | 2.17% | 3.07% | Upgrade
|
| Profit Margin | 1.24% | 0.89% | 0.51% | 0.61% | 1.32% | Upgrade
|
| Free Cash Flow Margin | -1.05% | -2.13% | -0.67% | -1.96% | -2.25% | Upgrade
|
| EBITDA | 3,814 | 2,391 | 1,266 | 596.27 | 784.78 | Upgrade
|
| EBITDA Margin | 4.98% | 4.28% | 3.73% | 2.68% | 3.61% | Upgrade
|
| D&A For EBITDA | 200.76 | 133.16 | 114.18 | 114.04 | 117.43 | Upgrade
|
| EBIT | 3,614 | 2,258 | 1,152 | 482.22 | 667.35 | Upgrade
|
| EBIT Margin | 4.72% | 4.04% | 3.39% | 2.17% | 3.07% | Upgrade
|
| Effective Tax Rate | 11.64% | 12.62% | 20.42% | 2.53% | 26.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.